EFFECTIVENESS OF MUSTA-TAKRA BASTI IN THE MANAGEMENT OF ULCERATIVE COLITIS (PITTAJA GRAHANI) – A CASE REPORT

Ulcerative colitis is an idiopathic inflammatory bowel disease causing inflammation and ulcers in the rectum and colon. Ulcerative colitis affects approximately 5,00,000 individuals in US with an incidence of 8-12 per 1,00,000 population per year. It is manifested as ano-rectal bleeding with increased frequency of bowel evacuation, general debility. In the contemporary science treatment is Corticosteroids, 5-Aminosalicylates, Anti-TNF therapy which results in other complications and the disease may even relapse after a period of time. A 62 years old female Patient attended OPD with diffuse abdominal pain, loose stools 10-15 times a day with blood, debility and weight loss. Patient was known case of ulcerative colitis since 6 years receiving treatment from contemporary science but she was not getting any satisfactory relief. Patient was treated with the concept of Pittaja Grahani in Ayurveda. Objective: To improve the signs and symptoms of the ulcerative colitis, to prevent from all possible intestinal and extra-intestinal complications related to ulcerative colitis finally to cure the disease. Method: Musta-Takra Basti was administered for 16 days along with other Ayurvedic drugs and signs and symptoms were evaluated daily. Result: Patient responded well with much improvement in her general condition. Frequency of defecation is decreased, no bleeding per rectum and other signs and symptoms were relieved. Conclusion: This study can be useful for reducing the need of steroids and surgical procedures in the patient of ulcerative colitis Hence Ayurveda treatment can be a promising alternative, safe and convenient treatment in the management of Ulcerative colitis

Estimation of population variance in successive sampling

Successive sampling, Class of estimators, Bias and Mean Square Error,

Global Burden of Cardiovascular Diseases and Risks, 1990-2022

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a multinational collaborative research study with >10,000 collaborators around the world. GBD generates a time series of summary measures of health, including prevalence, cause-specific mortality (CSMR), years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) to provide a comprehensive view of health burden for a wide range of stakeholders including clinicians, public and private health systems, ministries of health, and other policymakers. These estimates are produced for 371 causes of death and 88 risk factors according to mutually exclusive, collectively exhaustive hierarchies of health conditions and risks. The study is led by a principal investigator and governed by a study protocol, with oversight from a Scientific Council, and an Independent Advisory Committee.1 GBD is performed in compliance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).2 GBD uses de-identified data, and the waiver of informed consent was reviewed and approved by the University of Washington Institutional Review Board (study number 9060). This almanac presents results for 18 cardiovascular diseases (CVD) and the CVD burden attributed to 15 risk factors (including an aggregate grouping of dietary risks) by GBD region. A summary of methods follows. Additional information can be found online at https://ghdx.healthdata.org/record/ihme-data/cvd-1990-2022, including:Funding was provided by the Bill and Melinda Gates Foundation, and the American College of Cardiology Foundation. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The contents and views expressed in this report are those of the authors and do not necessarily reflect the official views of the National Institutes of Health, the Department of Health and Human Services, the U.S. Government, or the affiliated institutions